Immix Biopharma, Inc

75 articles about Immix Biopharma, Inc

• Immix Biopharma Receives Institutional Review Board Approval to Enroll Pediatric Patients in Upcoming IMX-110 Clinical Trial

  11/11/2022

  Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, today announced that it has received Institutional Review Board (“IRB”) approval to enroll pediatric patients in its upcoming IMX-110 clinical trial.

• Immix Biopharma to Present Milestones Achieved to Enable Kick-Off of 2 IMX-110 Clinical Trials at the 2022 ThinkEquity Conference on October 26

  10/25/2022

  Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that Chief Executive Officer Ilya Rachman, MD, PhD, and Chief Financial Officer Gabriel Morris will present a company overview and milestones achieved to enable kick-off of 2 IMX-110 clinical trials at the ThinkEquity Conference at the Mandarin Oriental Hotel in New York, New York on Wednesday, October 26, 2022 at 2:00 PM ET.

• ImmixBio Approves 4 Additional Clinical Trial Sites for IMX-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead Site

  10/18/2022

  Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced that it has approved 4 additional clinical trial sites for IMX-110 clinical trials, complementing existing soft tissue sarcoma lead clinical trial site in California.

• ImmixBio Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical Trials

  9/7/2022

  Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, today announced that it has completed Good Manufacturing Practice (“GMP”) manufacturing of a scaled-up batch of IMX-110 for clinical trials.

• ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study

  5/20/2022

  Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), today announced positive interim study data showing that after one cycle of treatment, ImmixBio’s lead candidate IMX-110 produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug) in a connective tissue cancer Soft Tissue Sarcoma (STS) mice study.

• Immix Biopharma Announces Share Repurchase Program

  5/9/2022

  Immix Biopharma, Inc. announced that its board of directors has authorized a share repurchase program to acquire up to $1 million of the Company's common stock.

• ImmixBio Management Discusses Key Milestones, Drug Development Timelines and the IMMX Advantage at IMMX Milestone Day Event Held on April 5, 2022

  4/5/2022

  Immix Biopharma, Inc. announced that management discussed key milestones, drug development timelines and the IMMX Advantage at its Milestone Day Event held at 9:30am ET on April 5, 2022.

• Immix Biopharma, Inc. Announces IMMX Milestone Day to be Held on April 5, 2022

  3/7/2022

  Immix Biopharma, Inc. today announced the IMMX Milestone Day Event, to be held on April 5, 2022.

• ImmixBio Initiates GMP Manufacturing of IMX-120, a Biologic for Inflammatory Bowel Disease

  2/22/2022

  Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “we” or “us”), today announced that it has initiated Good Manufacturing Practice (“GMP”) manufacturing of IMX-120, a biologic for inflammatory bowel disease (“IBD”). ImmixBio anticipates filing an IND for IMX-120 in 2023, representing a significant milestone on ImmixBio’s path to clinical trials for IMX-120 in inflammatory bowel disease.

• ImmixBio Management Answers Top-Voted Investor Questions at IMMX Investors Day February 1, 2022

  2/1/2022

  Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, today announced that management has answered top-voted questions submitted by verified IMMX shareholders at the IMMX Investors Day Event on February 1, 2022 at 9:30am ET.

• ImmixBio Initiates IMX-110 GMP Manufacturing Scale-Up, Potentially Accelerating Clinical Trial Data

  1/31/2022

  Immix Biopharma, Inc. today announced that it has initiated IMX-110 Good Manufacturing Practice (“GMP”) scale-up manufacturing, potentially accelerating the timeline to clinical data from two ImmixBio clinical trials planned for 2022.

• IMX-110 + anti-PD-1 Combination Produced Extended Median Survival in Genetic Pancreatic Cancer Mouse Model, Bolstering Planned 2022 IMX-110 Combination Clinical Trial Rationale

  1/25/2022

  Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), today announced data showing that IMX-110 + anti-PD-1 produced 63-day median survival in a genetic pancreatic cancer mouse model in which mice develop their own pancreatic cancer and have an intact immune system.

• ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data Demonstrating 100% Completion of Planned Treatment Cycles

  1/19/2022

  Immix Bio today announced positive interim clinical trial safety data demonstrating 100% completion of IMX-110 planned treatment cycles in its ongoing Phase 1b/2a clinical trial.

• ImmixBio IMX-110 Produced 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study

  1/12/2022

  Immix Biopharma, Inc. today announced study data showing that ImmixBio’s lead candidate IMX-110 produced a 50% response rate in a first-line-therapy-resistant cancer.

• Immix Biopharma Announces IMMX Investors Day to be Held on February 1, 2022 + Q&A Platform for All Shareholders

  1/6/2022

  Immix Biopharma, Inc. announced the IMMX Investors Day Event, to be held on February 1, 2022, and the launch of an online Q&A platform for all shareholders to submit questions in advance.

• U.S. Food and Drug Administration Approves Immix Biopharma Rare Pediatric Disease Designation for IMX-110 as a Treatment for Life-Threatening Pediatric Cancer in Children

  1/3/2022

  Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for IMX-110 for the treatment of a life-threatening form of pediatric cancer in children, rhabdomyosarcoma.

• Immix Biopharma, Inc. Announces Closing of Initial Public Offering

  12/20/2021

  Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced the closing of its initial public offering of 4,200,000 shares of its common stock at a public offering price of $5.00 per share.

• Immix Biopharma, Inc. Announces Pricing of Initial Public Offering

  12/15/2021

  Immix Biopharma, Inc. announced the pricing of its initial public offering of 4,200,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $21,000,000 before deducting underwriting discounts, commissions and offering expenses.

• ImmixBio Announces FDA Orphan Drug Designation for IMX-110 for the Treatment of Soft Tissue Sarcoma

  9/30/2021

  Immix Biopharma, Inc. ("ImmixBio"), a biotechnology company pioneering Tissue Specific Therapeutics (TSTx)TM for oncology and inflammation, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to IMX-110 for the treatment of soft tissue sarcoma.

• ImmixBio Announces Clinical Trial and Supply Agreement with BeiGene to Evaluate Combination of IMX-110 and Tislelizumab in Solid Tumors

  8/27/2021

  Immix Biopharma, Inc. ("ImmixBio") today announced a clinical trial and supply agreement with BeiGene, Ltd. to evaluate the safety, tolerability and efficacy of combining IMX-110 with TME Normalization™ Technology